» Articles » PMID: 24023735

Dynamics of DNA Damage Induced Pathways to Cancer

Overview
Journal PLoS One
Date 2013 Sep 12
PMID 24023735
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy is commonly used in cancer treatments, however only 25% of cancers are responsive and a significant proportion develops resistance. The p53 tumour suppressor is crucial for cancer development and therapy, but has been less amenable to therapeutic applications due to the complexity of its action, reflected in 66,000 papers describing its function. Here we provide a systematic approach to integrate this information by constructing a large-scale logical model of the p53 interactome using extensive database and literature integration. The model contains 206 nodes representing genes or proteins, DNA damage input, apoptosis and cellular senescence outputs, connected by 738 logical interactions. Predictions from in silico knock-outs and steady state model analysis were validated using literature searches and in vitro based experiments. We identify an upregulation of Chk1, ATM and ATR pathways in p53 negative cells and 61 other predictions obtained by knockout tests mimicking mutations. The comparison of model simulations with microarray data demonstrated a significant rate of successful predictions ranging between 52% and 71% depending on the cancer type. Growth factors and receptors FGF2, IGF1R, PDGFRB and TGFA were identified as factors contributing selectively to the control of U2OS osteosarcoma and HCT116 colon cancer cell growth. In summary, we provide the proof of principle that this versatile and predictive model has vast potential for use in cancer treatment by identifying pathways in individual patients that contribute to tumour growth, defining a sub population of "high" responders and identification of shifts in pathways leading to chemotherapy resistance.

Citing Articles

A Bioinformatics-Assisted Review on Iron Metabolism and Immune System to Identify Potential Biomarkers of Exercise Stress-Induced Immunosuppression.

Bonilla D, Moreno Y, Petro J, Forero D, Vargas-Molina S, Odriozola-Martinez A Biomedicines. 2022; 10(3).

PMID: 35327526 PMC: 8945881. DOI: 10.3390/biomedicines10030724.


Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics.

Gondal M, Chaudhary S Front Oncol. 2021; 11:712505.

PMID: 34900668 PMC: 8652070. DOI: 10.3389/fonc.2021.712505.


Update on biology and management of mesothelioma.

Asciak R, George V, Rahman N Eur Respir Rev. 2021; 30(159).

PMID: 33472960 PMC: 9489032. DOI: 10.1183/16000617.0226-2020.


Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells.

Lamboy-Caraballo R, Ortiz-Sanchez C, Acevedo-Santiago A, Matta J, Monteiro A, Armaiz-Pena G Int J Mol Sci. 2020; 21(6).

PMID: 32213975 PMC: 7139728. DOI: 10.3390/ijms21062250.


Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer.

Buiga P, Elson A, Tabernero L, Schwartz J Genes (Basel). 2019; 10(8).

PMID: 31357550 PMC: 6723192. DOI: 10.3390/genes10080568.


References
1.
Blagosklonny M . Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors. Oncogene. 2001; 20(3):395-8. DOI: 10.1038/sj.onc.1204055. View

2.
Yee K, Vousden K . Complicating the complexity of p53. Carcinogenesis. 2005; 26(8):1317-22. DOI: 10.1093/carcin/bgi122. View

3.
Moll U, Petrenko O . The MDM2-p53 interaction. Mol Cancer Res. 2004; 1(14):1001-8. View

4.
Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer J, Liu M . Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther. 2008; 7(6):1533-42. PMC: 2494594. DOI: 10.1158/1535-7163.MCT-08-0140. View

5.
Rodriguez A, Sosa D, Torres L, Molina B, Frias S, Mendoza L . A Boolean network model of the FA/BRCA pathway. Bioinformatics. 2012; 28(6):858-66. DOI: 10.1093/bioinformatics/bts036. View